Pharmaceuticals company Piramal Pharma announced Q3FY25 results Revenue from Operations: Rs 2,204 crore, up 13% YoY from Rs 1,959 crore CDMO: Rs 1,278 crore, up 13% YoY from Rs 1,134 crore CHG: Rs 654 crore, up 14% YoY from Rs 576 crore ICH: Rs 278 crore, up 10% YoY from Rs 252 crore EBITDA: Rs 350 crore, up 6% YoY from Rs 330 crore EBITDA Margin: 16%, down 1% YoY from 17% Share of Net Profit of Associates: Rs 17 crore, up 22% YoY from Rs 14 crore Net Profit After Tax: Rs 4 crore, down 64% YoY from Rs 10 crore Nandini Piramal, Chairperson, Piramal Pharma, said: “FY25 so far has been a steady year for the Company with revenue growth of 14% and EBITDA growing at 20%. Our CDMO business continues to deliver robust performance with 18% revenue growth along with EBITDA margin improvement in 9MFY25. This performance was largely led by innovation related work. Our CHG business registered an early-teen revenue growth during the quarter on the back of strong volume growth in our Inhalation Anesthesia portfolio. In our ICH business, power brands continue to register about 19% growth. The quarter also marked a significant milestone in our journey towards sustainable manufacturing with the conversion of coal-fired steam boiler at our Digwal facility to operate on biomass briquettes. This will significantly reduce our GHG emissions - underscoring our unwavering commitment towards the planet.” Result PDF